Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVRA vs AVASTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.
Onchocerciasis (river blindness),Strongyloidiasis (threadworm infection),Scabies (off-label, FDA-approved for scabies in certain contexts; also used off-label for head lice, pediculosis, and various parasitic infections)
Metastatic colorectal cancer (first- or second-line in combination with intravenous 5-fluorouracil-based chemotherapy),Non-small cell lung cancer (first-line in combination with carboplatin and paclitaxel for unresectable, locally advanced, recurrent or metastatic non-squamous disease),Glioblastoma (single agent for progressive disease following prior therapy),Metastatic renal cell carcinoma (in combination with interferon alfa),Ovarian epithelial, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel and carboplatin or pegylated liposomal doxorubicin for platinum-sensitive recurrent disease; as a single agent for platinum-resistant recurrent disease),Cervical cancer (in combination with paclitaxel and cisplatin or topotecan for persistent, recurrent, or metastatic disease),Off-label uses: age-related macular degeneration (intravitreal), hereditary hemorrhagic telangiectasia, ovarian cancer (first-line maintenance), breast cancer (not FDA approved)
Intravenous 500 mg every 6 hours.
5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Terminal half-life approximately 20 days (range 11–50 days) in patients; supports dosing every 2–3 weeks
Primarily metabolized by CYP3A4 in the liver; also a substrate for P-glycoprotein (P-gp) transporter.
Bevacizumab is primarily metabolized via proteolytic degradation into small peptides and amino acids. No specific metabolic enzymes are involved; it is not metabolized by cytochrome P450 enzymes.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Primarily via reticuloendothelial system and proteolytic catabolism; negligible renal excretion (<1% unchanged in urine)
Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Bound primarily to albumin and other plasma proteins; approximately 95–100% bound (saturable binding to Fc Rn may occur)
0.6-0.8 L/kg, indicating distribution into total body water with some extravascular binding; increased in heart failure or severe hepatic disease.
Vd approximately 2.9–3.7 L (not weight-normalized; small Vd consistent with large monoclonal antibody confined mainly to plasma and interstitial space)
Oral: 70-80% (extensive first-pass metabolism reduces from 90% absorbed); Intravenous: 100%.
Only available as intravenous infusion; bioavailability 100% by IV route; not administered subcutaneously or orally (no bioavailability data for other routes)
GFR >60 m L/min: 500 mg q6h; GFR 30-60: 250 mg q6h; GFR 15-30: 250 mg q12h; GFR <15: 250 mg q24h.
No dose adjustment is recommended for patients with renal impairment; however, be cautious in severe renal impairment (GFR <30 m L/min) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg q6h; Child-Pugh C: 250 mg q12h.
No specific dose adjustment guidelines exist for hepatic impairment based on Child-Pugh score; use with caution in severe hepatic impairment.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Safety and efficacy in pediatric patients have not been established; no standard dosing guidelines available.
Same as adult; monitor renal function and adjust per GFR.
No specific dose adjustment is required for elderly patients; however, monitor for increased incidence of arterial thromboembolic events, hypertension, and proteinuria as seen in clinical trials.
None.
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE. Gastrointestinal perforations occur in up to 2.4% of patients. Discontinue for perforations, tracheoesophageal fistula, or wound dehiscence. Severe or fatal hemorrhage, including hemoptysis and gastrointestinal bleeding, has occurred; monitor for bleeding.
Potential for severe adverse reactions (Mazzotti reaction) in onchocerciasis patients; neurotoxicity (especially in elderly or patients with high drug levels); avoid use in patients with impaired hepatic function; caution with concomitant use of CNS depressants; not recommended in pregnancy (Category C).
Gastrointestinal perforations and fistulae (including tracheoesophageal),Surgery and wound healing complications: do not administer within 28 days of major surgery or until wound is fully healed,Hemorrhage: severe or fatal pulmonary hemorrhage (particularly in squamous NSCLC), gastrointestinal bleeding, and cerebral hemorrhage,Non-gastrointestinal fistula formation (including bronchopleural, biliary, and vaginal),Arterial thromboembolic events (e.g., stroke, myocardial infarction): risk increased in patients ≥65 years of age,Hypertension: monitor blood pressure; may require antihypertensive therapy,Reversible posterior leukoencephalopathy syndrome (RPLS),Proteinuria: monitor urine protein; discontinue if nephrotic syndrome develops,Ovarian failure: may impair fertility in women,Congestive heart failure: increased incidence in patients receiving anthracyclines or with prior chest radiation
Hypersensitivity to ivermectin or any component of the formulation; not for use in pediatric patients weighing less than 15 kg for scabies treatment (due to risk of neurotoxicity).
Known hypersensitivity to bevacizumab or any components of the formulation,Recent hemoptysis (≥2.5 m L of red blood) within 21 days prior to treatment,Untreated central nervous system metastases (due to risk of bleeding; treat prior to bevacizumab)
No food interactions with IVRA technique; however, lidocaine administration may be affected by grapefruit juice (inhibits metabolism) — avoid grapefruit juice before procedure.
No specific food interactions known. No restrictions beyond general dietary advice for cancer patients.
IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal nephrotoxicity, oligohydramnios, and premature ductus arteriosus closure.
Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal impairment, and spontaneous abortion reported. Avoid use unless potential benefit justifies risk.
Excreted into breast milk in low amounts; M/P ratio 0.3. Avoid use due to potential adverse effects in nursing infants (renal impairment, bleeding).
No data on excretion in human milk. M/P ratio unknown. Due to potential for adverse effects in nursing infants, breastfeeding is not recommended during therapy and for at least 6 months after last dose.
No dose adjustment is recommended as IVRA is contraindicated. In case of inadvertent use in pregnancy, discontinue immediately.
No formal dose adjustment studies in pregnancy. Increased volume of distribution and clearance may occur, but no dose changes recommended. Use lowest effective dose with careful monitoring.
IVRA (intravenous regional anesthesia) is not a drug but a technique. For Bier block using lidocaine, use 0.5% preservative-free lidocaine, 3 mg/kg for upper extremity. Avoid in patients with sickle cell disease or severe hypertension. Monitor for tourniquet pain after 30 minutes; deflate tourniquet gradually to prevent systemic toxicity.
Monitor blood pressure closely; hypertension is common. Hold therapy 28 days before elective surgery due to impaired wound healing. Use with caution in patients with cardiovascular disease or history of arterial thromboembolism. Proteinuria monitoring required; urine dipstick at baseline and regularly. Avoid in patients with recent hemoptysis or untreated CNS metastases.
You will receive local anesthetic injected into a vein in your arm after a tourniquet is applied.,The tourniquet will be kept inflated during the procedure to keep the medication in the arm.,You may feel a burning sensation when the medication is injected, which is normal.,Do not remove the tourniquet yourself; it will be deflated slowly by the doctor to prevent side effects.,Report any chest discomfort, ringing in ears, or metallic taste immediately.
Report any signs of bleeding, such as unusual bruising, nosebleeds, or blood in urine/stool.,Inform your doctor immediately if you experience severe headache, vision changes, confusion, or seizures (signs of PRES).,Avoid surgery or dental procedures without notifying your oncologist; therapy may need to be paused.,Females of childbearing age must use effective contraception during and for 6 months after treatment.,Do not drive if you experience vision problems or dizziness from therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVRA vs AVASTIN, answered by our medical review team.
IVRA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.. AVASTIN is a Antineoplastic (Angiogenesis Inhibitor) that works by Bevacizumab is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells, thereby inhibiting angiogenesis and tumor growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVRA and AVASTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVRA is: Intravenous 500 mg every 6 hours.. The standard adult dose of AVASTIN is: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks for metastatic colorectal cancer; 10 mg/kg intravenously every 2 weeks for non-small cell lung cancer; 15 mg/kg intravenously every 3 weeks for glioblastoma; 15 mg/kg intravenously every 3 weeks for metastatic renal cell carcinoma (in combination with interferon alfa).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVRA and AVASTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVRA is classified as Category C. IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal n. AVASTIN is classified as Category C. Pregnancy Category C. First trimester: Risk of fetal malformations based on animal studies; no adequate human studies. Second and third trimesters: Oligohydramnios, fetal renal imp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.